Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroblastoma | 30 | 2024 | 1250 | 3.080 |
Why?
|
3-Iodobenzylguanidine | 7 | 2023 | 114 | 0.810 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2022 | 891 | 0.740 |
Why?
|
Interleukin-2 | 3 | 2019 | 1889 | 0.680 |
Why?
|
Isotretinoin | 1 | 2019 | 134 | 0.590 |
Why?
|
Facial Paralysis | 2 | 2021 | 346 | 0.480 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2024 | 9280 | 0.460 |
Why?
|
Sesquiterpenes | 4 | 2003 | 176 | 0.400 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2016 | 732 | 0.370 |
Why?
|
Aminopeptidases | 3 | 2005 | 95 | 0.350 |
Why?
|
Antibodies, Monoclonal | 3 | 2019 | 9177 | 0.340 |
Why?
|
Metalloendopeptidases | 3 | 2005 | 393 | 0.320 |
Why?
|
Chlorobenzenes | 2 | 2005 | 28 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 11742 | 0.280 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1159 | 0.250 |
Why?
|
Radiotherapy | 1 | 2011 | 1498 | 0.240 |
Why?
|
Neoplasms | 8 | 2024 | 22173 | 0.230 |
Why?
|
Child, Preschool | 24 | 2024 | 42232 | 0.230 |
Why?
|
Chromosomes, Human, Pair 16 | 2 | 2002 | 343 | 0.230 |
Why?
|
Child | 31 | 2024 | 80158 | 0.220 |
Why?
|
Antineoplastic Agents | 9 | 2019 | 13642 | 0.210 |
Why?
|
Angiogenesis Inhibitors | 3 | 2001 | 2048 | 0.200 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2005 | 3605 | 0.190 |
Why?
|
Salvage Therapy | 2 | 2021 | 1263 | 0.190 |
Why?
|
Whole-Body Irradiation | 2 | 2016 | 433 | 0.170 |
Why?
|
Neovascularization, Pathologic | 2 | 2005 | 2645 | 0.150 |
Why?
|
Lymphoproliferative Disorders | 1 | 2021 | 531 | 0.140 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2017 | 131 | 0.140 |
Why?
|
Gene Fusion | 1 | 2019 | 356 | 0.140 |
Why?
|
Palliative Care | 2 | 2023 | 3598 | 0.140 |
Why?
|
Septum Pellucidum | 1 | 1996 | 54 | 0.130 |
Why?
|
Attitude to Death | 1 | 2019 | 400 | 0.130 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5305 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1126 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 339 | 0.130 |
Why?
|
Pyrroles | 2 | 2011 | 1125 | 0.120 |
Why?
|
Adolescent | 19 | 2024 | 88326 | 0.120 |
Why?
|
Carbazoles | 2 | 2019 | 220 | 0.120 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4853 | 0.120 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 612 | 0.120 |
Why?
|
Infant | 13 | 2024 | 36193 | 0.120 |
Why?
|
Bone Neoplasms | 2 | 2017 | 2529 | 0.120 |
Why?
|
Hypopituitarism | 1 | 1996 | 250 | 0.120 |
Why?
|
Cyclohexanes | 4 | 2003 | 152 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5314 | 0.110 |
Why?
|
Maximum Tolerated Dose | 5 | 2021 | 883 | 0.110 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2022 | 5672 | 0.110 |
Why?
|
Azacitidine | 1 | 2015 | 336 | 0.110 |
Why?
|
Combined Modality Therapy | 6 | 2016 | 8527 | 0.110 |
Why?
|
Tubulin Modulators | 1 | 2013 | 107 | 0.110 |
Why?
|
Indoles | 2 | 2011 | 1833 | 0.110 |
Why?
|
Radionuclide Imaging | 1 | 2017 | 1972 | 0.110 |
Why?
|
Optic Nerve | 1 | 1996 | 572 | 0.100 |
Why?
|
Feasibility Studies | 3 | 2019 | 5247 | 0.100 |
Why?
|
Adenoma | 1 | 2023 | 2163 | 0.100 |
Why?
|
Tympanic Membrane | 1 | 2014 | 232 | 0.100 |
Why?
|
Leukemia | 1 | 2000 | 1522 | 0.100 |
Why?
|
Lymphocyte Count | 2 | 2012 | 778 | 0.100 |
Why?
|
Humans | 46 | 2024 | 761596 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3639 | 0.100 |
Why?
|
Mice, Nude | 3 | 2005 | 3614 | 0.100 |
Why?
|
Tumor Cells, Cultured | 4 | 2005 | 6131 | 0.100 |
Why?
|
Facial Nerve | 1 | 2014 | 277 | 0.100 |
Why?
|
Camptothecin | 1 | 2014 | 591 | 0.090 |
Why?
|
Receptors, KIR | 1 | 2010 | 110 | 0.090 |
Why?
|
Radiopharmaceuticals | 2 | 2017 | 2650 | 0.090 |
Why?
|
Receptor, trkB | 1 | 2011 | 124 | 0.090 |
Why?
|
Adoptive Transfer | 1 | 2012 | 819 | 0.090 |
Why?
|
Parents | 2 | 2023 | 3563 | 0.080 |
Why?
|
Mice, SCID | 3 | 2005 | 2626 | 0.080 |
Why?
|
Survivors | 1 | 2000 | 2371 | 0.080 |
Why?
|
Recombinant Proteins | 1 | 2019 | 6534 | 0.080 |
Why?
|
Treatment Outcome | 11 | 2022 | 64685 | 0.080 |
Why?
|
Receptors, Interleukin-2 | 1 | 2010 | 562 | 0.080 |
Why?
|
Communication | 2 | 2020 | 3875 | 0.080 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1189 | 0.080 |
Why?
|
Transplantation, Autologous | 3 | 2022 | 2115 | 0.080 |
Why?
|
Education | 1 | 2011 | 537 | 0.080 |
Why?
|
Vincristine | 2 | 2021 | 1036 | 0.080 |
Why?
|
Prospective Studies | 6 | 2023 | 54423 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2023 | 13381 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2015 | 1051 | 0.070 |
Why?
|
Receptors, IgG | 1 | 2010 | 559 | 0.070 |
Why?
|
Cyclophosphamide | 2 | 2005 | 2220 | 0.070 |
Why?
|
Young Adult | 9 | 2023 | 59260 | 0.070 |
Why?
|
Loss of Heterozygosity | 3 | 2006 | 662 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2015 | 10194 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 1008 | 0.070 |
Why?
|
Oncogene Proteins | 3 | 2005 | 719 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 2332 | 0.070 |
Why?
|
Male | 19 | 2024 | 360846 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 5 | 2023 | 5672 | 0.060 |
Why?
|
Adult | 9 | 2023 | 221210 | 0.060 |
Why?
|
Dendritic Cells | 1 | 2015 | 2747 | 0.060 |
Why?
|
Sulfonamides | 1 | 2013 | 1979 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5821 | 0.060 |
Why?
|
Nurses | 1 | 2013 | 2478 | 0.060 |
Why?
|
Female | 19 | 2024 | 392705 | 0.050 |
Why?
|
Thiazoles | 1 | 2011 | 1517 | 0.050 |
Why?
|
Radiotherapy Dosage | 2 | 2024 | 2898 | 0.050 |
Why?
|
Bone Marrow Transplantation | 2 | 2001 | 2693 | 0.050 |
Why?
|
Prognosis | 5 | 2022 | 29629 | 0.050 |
Why?
|
Mice, Inbred Strains | 1 | 2005 | 1762 | 0.050 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2003 | 418 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2015 | 10451 | 0.050 |
Why?
|
Genes, myc | 1 | 2003 | 390 | 0.050 |
Why?
|
Lactams, Macrocyclic | 1 | 2023 | 318 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 617 | 0.050 |
Why?
|
Caregivers | 1 | 2013 | 2238 | 0.050 |
Why?
|
Chromosome Aberrations | 2 | 2006 | 1768 | 0.050 |
Why?
|
Indazoles | 1 | 2022 | 304 | 0.050 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 33 | 0.040 |
Why?
|
Osteoradionecrosis | 1 | 2000 | 51 | 0.040 |
Why?
|
Genetic Linkage | 2 | 2002 | 2341 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 2003 | 754 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2012 | 4758 | 0.040 |
Why?
|
Aminopyridines | 1 | 2023 | 573 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2016 | 2850 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1896 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2022 | 2425 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12973 | 0.040 |
Why?
|
Therapies, Investigational | 1 | 2019 | 111 | 0.040 |
Why?
|
Pyrimidines | 1 | 2011 | 3028 | 0.040 |
Why?
|
Goals | 1 | 2023 | 711 | 0.040 |
Why?
|
Calcitonin | 1 | 2019 | 329 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2013 | 4485 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6815 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2000 | 390 | 0.040 |
Why?
|
Neovascularization, Physiologic | 2 | 2003 | 1349 | 0.040 |
Why?
|
Cell Division | 2 | 2003 | 4465 | 0.040 |
Why?
|
Benzamides | 1 | 2022 | 1371 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2000 | 678 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39106 | 0.030 |
Why?
|
Survival Analysis | 2 | 2009 | 10090 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8002 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2000 | 1386 | 0.030 |
Why?
|
Bone Marrow | 2 | 2009 | 2911 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2014 | 10766 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2024 | 80647 | 0.030 |
Why?
|
Nuclear Proteins | 3 | 2005 | 5799 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1078 | 0.030 |
Why?
|
Melanoma-Specific Antigens | 1 | 2015 | 74 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2000 | 642 | 0.030 |
Why?
|
Growth Disorders | 1 | 2000 | 655 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1626 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2006 | 8554 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2005 | 9542 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2005 | 6312 | 0.030 |
Why?
|
Stem Cell Transplantation | 2 | 2016 | 1600 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 610 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3492 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2003 | 6075 | 0.030 |
Why?
|
Suspensions | 1 | 2013 | 66 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1342 | 0.030 |
Why?
|
Genome, Human | 2 | 2006 | 4425 | 0.030 |
Why?
|
Infertility | 1 | 2000 | 654 | 0.030 |
Why?
|
Capsules | 1 | 2013 | 191 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 2017 | 1031 | 0.030 |
Why?
|
Transplantation Conditioning | 1 | 2000 | 1590 | 0.030 |
Why?
|
Mice | 5 | 2005 | 81539 | 0.030 |
Why?
|
Cholestasis | 1 | 1996 | 378 | 0.030 |
Why?
|
Radiation Injuries | 1 | 2000 | 1189 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2811 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2000 | 4615 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2000 | 1052 | 0.030 |
Why?
|
Blindness | 1 | 1996 | 584 | 0.030 |
Why?
|
Quality of Life | 3 | 2019 | 13367 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2003 | 2986 | 0.020 |
Why?
|
Recurrence | 2 | 2015 | 8466 | 0.020 |
Why?
|
Genomics | 2 | 2024 | 5821 | 0.020 |
Why?
|
Powders | 1 | 2011 | 80 | 0.020 |
Why?
|
Piperidines | 1 | 2019 | 1656 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2016 | 1440 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20568 | 0.020 |
Why?
|
Philadelphia | 1 | 2011 | 267 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 140 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4514 | 0.020 |
Why?
|
Syndrome | 1 | 1996 | 3267 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2002 | 17904 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2013 | 496 | 0.020 |
Why?
|
Furans | 1 | 2011 | 202 | 0.020 |
Why?
|
Motivation | 1 | 2019 | 2006 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2010 | 317 | 0.020 |
Why?
|
Hypoglycemia | 1 | 1996 | 883 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4915 | 0.020 |
Why?
|
Safety | 1 | 2013 | 1149 | 0.020 |
Why?
|
Animals | 5 | 2005 | 168475 | 0.020 |
Why?
|
Cardiomyopathies | 1 | 2000 | 1964 | 0.020 |
Why?
|
Emotions | 1 | 2019 | 2739 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2643 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 4576 | 0.020 |
Why?
|
Mutation | 2 | 2024 | 30053 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14608 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2015 | 1993 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12723 | 0.020 |
Why?
|
Antigens, Bacterial | 1 | 2012 | 1154 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 36426 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3251 | 0.020 |
Why?
|
Cognition Disorders | 1 | 2000 | 3980 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6484 | 0.020 |
Why?
|
Neutropenia | 1 | 2011 | 885 | 0.020 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 686 | 0.020 |
Why?
|
Immunologic Memory | 1 | 2012 | 1359 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 9610 | 0.020 |
Why?
|
Decision Making | 1 | 2019 | 3929 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 39969 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2013 | 1200 | 0.020 |
Why?
|
Influenza Vaccines | 1 | 2012 | 768 | 0.020 |
Why?
|
HLA Antigens | 1 | 2010 | 1328 | 0.020 |
Why?
|
Apoptosis | 1 | 2001 | 9490 | 0.020 |
Why?
|
Risk | 1 | 2016 | 9610 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2024 | 26202 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2217 | 0.010 |
Why?
|
Sarcoma | 1 | 2015 | 1801 | 0.010 |
Why?
|
Contrast Media | 1 | 2017 | 5307 | 0.010 |
Why?
|
Ligands | 1 | 2010 | 3272 | 0.010 |
Why?
|
Inhibitor of Differentiation Protein 2 | 1 | 2003 | 30 | 0.010 |
Why?
|
Transcription Factors | 1 | 2003 | 12130 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2013 | 1667 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2015 | 3617 | 0.010 |
Why?
|
Gene Targeting | 1 | 2006 | 838 | 0.010 |
Why?
|
Administration, Oral | 1 | 2011 | 4021 | 0.010 |
Why?
|
Immunotherapy, Adoptive | 1 | 2012 | 1469 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2015 | 5112 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5872 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2017 | 11120 | 0.010 |
Why?
|
Gene Dosage | 1 | 2006 | 1218 | 0.010 |
Why?
|
Fibrosarcoma | 1 | 2003 | 309 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 1551 | 0.010 |
Why?
|
Hospitals, Pediatric | 1 | 2011 | 1860 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2010 | 2201 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 2001 | 352 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4243 | 0.010 |
Why?
|
Hospitals | 1 | 2013 | 3883 | 0.010 |
Why?
|
Phosphorylation | 1 | 2011 | 8321 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2006 | 12794 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 18966 | 0.010 |
Why?
|
Pilot Projects | 1 | 2012 | 8633 | 0.010 |
Why?
|
Random Allocation | 1 | 2003 | 2395 | 0.010 |
Why?
|
Patient Selection | 1 | 2011 | 4244 | 0.010 |
Why?
|
Drug Design | 1 | 2003 | 1048 | 0.010 |
Why?
|
Gene Amplification | 1 | 2003 | 1089 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2015 | 7859 | 0.010 |
Why?
|
Heart | 1 | 2011 | 4404 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 2510 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13510 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 12990 | 0.010 |
Why?
|
Cornea | 1 | 2003 | 1333 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 26129 | 0.010 |
Why?
|
Pediatrics | 1 | 2011 | 3589 | 0.010 |
Why?
|
Cell Cycle | 1 | 2003 | 2932 | 0.010 |
Why?
|
Cohort Studies | 1 | 2017 | 41495 | 0.010 |
Why?
|
Models, Molecular | 1 | 2003 | 5439 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2003 | 2917 | 0.010 |
Why?
|
Pedigree | 1 | 2000 | 4542 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4431 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2006 | 9420 | 0.010 |
Why?
|
Mortality | 1 | 2001 | 2902 | 0.010 |
Why?
|
Risk Assessment | 1 | 2011 | 23996 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2003 | 14665 | 0.000 |
Why?
|
Middle Aged | 1 | 2002 | 220921 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2003 | 16990 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2001 | 20100 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2001 | 18255 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2003 | 21019 | 0.000 |
Why?
|